Resumen

Hepatocellular carcinoma (HCC) accounts for 70%-90% of primary liver cancers, and is the fifth most common cancer in Western countries.1 HCC is a rapidly evolving tumor, with difficult management and with a survival < 15% at 5 years despite new diagnostic technologies and new therapies have led to an improvement in patient outcomes. Several factors contribute to poor prognosis: the presence of a coexisting liver cirrhosis which limits responsiveness to systemic chemotherapy, the frequent association with comorbidities, the often delay of diagnosis. In this respect, to reduce diagnosis delay, international scientific societies such as the European Association for the Study of the Liver (EASL), the Japan Society of Hepatology (JSH) and the American Association for the Study of Liver Diseases (AASLD) proposed screening schedules for patients at risk of developing hepatocellular carcinoma.

Palabras clave:

2017-12-13   |   223 visitas   |   Evalua este artículo 0 valoraciones

Vol. 16 Núm.5. Septiembre-Octubre 2017 Pags. 699-701 Ann Hepatol 2017; 16(5)